Amsterdam, The Netherlands, 15 June 2021 – VectorY B.V., a biotech company focusing on the development of innovative gene therapy approaches for the treatment of muscular and neurodegenerative disorders through vectorized antibodies, today announces the appointments of Alexander Vos as Chief Executive Officer, and Dr. Sander van Deventer as Chief Technology Officer, effective immediately.
Alexander brings over 25 years of leadership experience in the biotech industry, having held senior positions at multiple private and public biopharma companies, such as Genzyme (Europe), Paion AG, and most recently, VarmX. Specifically, he brings many years of experience in cell and gene therapy as the CEO of PharmaCell BV, the leading European CDMO where he served from 2010 until 2017 when it was acquired by Lonza. He has been one of the industry pioneers laying the foundation in Europe for the global industry group Alliance for Regenerative Medicine and subsequently served on the executive board. Mr. Vos holds a MS in Pharmacy and Pharmacology from the University of Amsterdam and an MBA from Stanford University.
Dr. van Deventer joins VectorY following his most recent appointment at uniQure as its Executive Vice President, Research and Product Development. He is a leading expert in the drug development industry having brought to market several innovative drugs. Dr. van Deventer is a pioneer in the field of gene therapy. As one of the co-founders and Chief Medical Officer of uniQure’s predecessor Amsterdam Molecular Therapeutics (AMT) in 1998, he was instrumental in deploying uniQure’s strategies in gene therapy, its research activities, clinical development, process development, analytical development and vector development, culminating in the first ever commercially approved gene therapy, Glybera, in 2012. Dr. van Deventer is a trained internist and board-certified gastroenterologist. He received a Ph.D. from the University of Amsterdam.
Alexander Vos, CEO of VectorY, said:
“I feel very privileged to lead the distinguished team at VectorY. Our world-class team of scientists will be breaking new ground in the field of gene therapy, which is an area I have worked in for many years. I am proud to be able to support the team in developing new therapies for patients in the challenging field of neuroscience and muscular disorders. With today’s announcement of the €31m seed financing, co-led by Forbion and a leading global investment firm, we have the resources to drive the Company forward. We believe our novel vectorized antibody technology can have significant positive impact on patients’ lives.”
Carlo Incerti, Chairman of VectorY, commented:
“On behalf of the VectorY Board, I’d like to welcome Alexander and Sander to the Company. With significant experience in cell and gene therapy, their expertise will be critical to VectorY as it looks to establish pre-clinical proof of concept for vectorized antibodies in our target indications of ALS and other neurodegenerative disorders. I’d also like to take the opportunity to thank Marco Boorsma for his essential contribution as interim-CEO since the launch of the Company, especially for being instrumental in completing the €31 million seed financing round that was announced today.”
VectorY is a fully integrated gene therapy company focused on the development of innovative vectorized antibodies for muscular and neurodegenerative disorders, such as ALS. The Company was launched in October 2020 and has established its laboratories and offices at the Amsterdam Science Park in The Netherlands.
The Company has today announced the completion of a €31 million seed financing round, co-led by founding investor Forbion and a leading global investment firm. See the VectorY website for the full announcement: www.vectorytx.com.
VectorY combines the therapeutic potential of antibodies, RNA and gene therapy to develop long-lasting therapeutic solutions for muscular and neurodegenerative diseases with high unmet medical need. Founded in October 2020, and based in the Amsterdam Science Park, VectorY is a fully integrated gene therapy company focused on the development of innovative therapeutics based on a novel AAV gene therapy platform, antibody- and RNA-based targeted degradation technologies, and proprietary manufacturing technology. VectorY develops proprietary & partnered programs and product candidates are based on new technologies that will enable the next generation of highly scalable manufacturing processes within VectorY’s own manufacturing facilities. VectorY’s manufacturing capabilities will include a state-of-the-art multi-product GMP facility in the Netherlands, with the capability to deliver suspension based AAV viral vector manufacturing of up to 2000L for both clinical and commercial supply.
For more information, see www.vectorytx.com.
Forbion is a dedicated life sciences venture capital firm with offices in The Netherlands, Germany and Singapore. Forbion invests in life sciences companies that are active in the (bio-) pharmaceutical space.
Forbion manages well over EUR 1.7 billion across multiple fund strategies that cover all stages of (bio)pharmaceutical drug development. Forbion’s current team consists of 20 life sciences investment professionals that have built an impressive performance track record since the late nineties with successful investments in over 70 companies.
The firm is a signatory to the United Nations Principles for Responsible Investment. Besides financial objectives, Forbion selects investments that will positively affect the health and well-being of patients.
Its investors include the EIF, through its European Recovery Programme (ERP), LfA, Dutch Venture Initiative (DVI), AMUF and EFSI facilities and KfW Capital through the Programme, “ERP – Venture Capital Fonds investments”. Forbion operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and Germany.
For more information, please visit: www.forbion.com.
About BioGeneration Ventures (BGV)
BioGeneration Ventures (BGV) is a venture capital company, with a focus on early-stage European biotech companies. With a strong track record of significant financial returns through its investments in healthcare innovations and providing the expertise to build world-class companies, BGV manages over EUR 250 million of funds and invests in areas where true scientific innovations, unmet medical needs, and the potential to demonstrate a significant proof of concept all converge. BGV strives to work with founding teams to progress science and build successful companies and uses its experience to guide progress into clinical trials, leading to successful drug development and value realization for its investors. BGV applies its expertise in a rigorous process to select the most compelling opportunities with the best prospects for exit. The Company is based in Naarden, The Netherlands.
For more information, please visit: www.biogenerationventures.com.
For more information please contact: VectorY@instinctif.com
Melanie Toyne-SewellManaging Partner